European Archives - Page 671 of 1002 - European Medical Journal

Planning Your Next Move in Philadelphia Chromosome Positive Leukaemias

The meeting was arranged as a series of conversations between experts, following a question and answer format with two speakers in each presentation…

Polymorphisms in Multidrug Resistance Transporter Genes Affect the Duration of Molecular Response to Nilotinib in Chronic Myeloid Leukaemia Patients

Despite the high efficacy and improved clinical response of nilotinib in chronic myeloid leukaemia (CML), there is still a significant proportion of…

Review of the 23rd European Hematology Association Congress 2018

A warm welcome to the EMJ Hematology review of the landmark 23rd annual congress of the European Hematology Association (EHA).

EMJ Hematology 6.1 2018

This year’s eJournal presents key research, discussions, and future directions for the field of haematology. Highlights from the publication include an…

Editor's Pick: Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors

The introduction of tyrosine kinase inhibitors (TKI) has dramatically improved the prognosis of chronic myeloid leukaemia (CML) patients and, therefore…

Inherited Platelet Disorders Caused by Thrombopoietin Mutation

Thrombopoietin (THPO) and the interaction with its receptor c-Mpl have a nonredundant role in platelet biogenesis and maintenance of the haematopoietic…

Therapeutic Options in Myelodysplastic Syndromes: Established and Emerging Therapies

Although hypomethylating agents (HMA) have revolutionised the treatment of myelodysplastic syndromes (MDS), a significant proportion of patients either…

Bacterial Contamination of Platelet Transfusion Units Affects Platelet Haemostatic Function and Immunological Activity

Transfusion-associated bacterial infection is a major risk of platelet transfusion and can be fatal. The storage requirements of platelet concentrates…

Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy

The humanised anti-CD20 antibody (Ab) rituximab (RTX) has significantly improved the prognosis of B cell non-Hodgkin’s lymphomas (BNHL). However, major…

Lenalidomide: The Gift That Keeps on Giving

First-line therapy for indolent non-Hodgkin’s lymphoma usually consists of a combination of rituximab-based chemoimmunotherapy. Historically, first-line…